Ranbaxy Laboratories today surged over 10 per cent on the Bombay Stock Exchange, the biggest single-day gain so far this year, after health regulators in the UK and Australia approved its manufacturing facility at Paonta Sahib in Himachal Pradesh. At the end of trade, shares of Ranbaxy settled at Rs 160.20, up 10.22 per cent on the BSE.

During the day, the scrip had surged to an intra-day high of Rs 161.40, up 11.04 per cent over previous close.

Ranbaxy, which had touched its 52-week low levels on March 12, has gained over 19 per cent since then driven by massive surge of today’s 10 per cent, the biggest single day so far this year.

The drug firm today said the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Australia’s Therapeutic Goods Administration (TGA) have issued Good Manufacturing Practice (GMP) certificates for the company’s manufacturing site at Paonta Sahib in Himachal Pradesh, following a joint audit conducted in October last year.

On the National Stock Exchange, the scrip closed at Rs 161.15, up 10.83 per cent over last closing. During the day the scrip soared 12.38 per cent to touch a high of Rs 163.40.

Ranbaxy, in which Japanese firm Daiichi Sankyo holds a controlling stake, has seen erosion in its valuation by nearly 37 per cent so far this year.

Meanwhile, Ranbaxy Laboratories has bought shares worth over Rs 22.60 crorein financial services firm Religare Enterprises through an open market transaction.

Ranbaxy has purchased six lakh shares at a price of Rs 376.71 a piece, aggregating Rs 22.60 crore, according to bulk deal data available on the National Stock Exchange.